ArticleBlood2017
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06224049 (A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection), which is not on this map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06224049 early_phase1unknown statusnot on this mapstarted 2023, after this paper: background citation
A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2021Trial
- Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing.Hematology. American Society of Hematology. Education Program · 2025Review
- Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.Leukemia · 2025Article
- Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.Cancer immunology research · 2025Article
- Phase I/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation: study rational and design.Frontiers in immunology · 2025Article
- Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.Human vaccines & immunotherapeutics · 2024Review
- T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Article
- Article
- Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies.Cancers · 2023Article
- Potency assays and biomarkers for cell-based advanced therapy medicinal products.Frontiers in immunology · 2023Review
- Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Cancer research · 2022Review
- Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.Blood · 2022Article
- Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.International journal of molecular sciences · 2022Review
- Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.Cancer treatment and research · 2022Article
- Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.Cancers · 2021Review
- Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.International journal of molecular sciences · 2021Review
- Review
- Targeting public neoantigens for cancer immunotherapy.Nature cancer · 2021Review
- Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.International journal of molecular sciences · 2021Review
Corrections and comments
- Commented on by
Authors and funding
25 authors at 5 institutions in 2 countries.
Patrizia ComoliPediatric Hematology/Oncology and.ORCID 0000-0001-5964-0553
Sabrina BassoPediatric Hematology/Oncology and.ORCID 0000-0003-2377-815X
Giovanni RivaSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Patrizia BarozziSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.ORCID 0000-0002-8936-1114
Ilaria GuidoPediatric Hematology/Oncology and.
Antonella GurradoPediatric Hematology/Oncology and.
Giuseppe QuartuccioPediatric Hematology/Oncology and.
Laura RubertPediatric Hematology/Oncology and.
Ivana LagrecaSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Daniela ValleriniSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Fabio ForghieriSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Monica MorselliSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Paola BrescianiSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Angela CuoghiSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Ambra PaoliniSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Elisabetta ColaciSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Roberto MarascaSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Antonio CuneoSection of Hematology, University of Ferrara, Ferrara, Italy.
Lorenzo IughettiSection of Pediatric Hemato-Oncology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.
Tommaso TrentiDepartment of Laboratory Medicine and Pathology, Unità Sociosanitaria Locale, Modena, Italy; and.
Franco NarniSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.
Robin FoàHematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.
Marco ZeccaPediatric Hematology/Oncology and.ORCID 0000-0002-8818-1744
Mario LuppiSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.ORCID 0000-0002-0373-1154
Leonardo PotenzaSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy.ORCID 0000-0002-2738-6105
University of Modena and Reggio Emilia · ITPalmetto Hematology Oncology · USAzienda Unita' Sanitaria Locale Di Modena · ITPoliclinico Umberto I · ITUniversity of Ferrara · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the emergence of bone marrow (BM)-resident
Indexed as
Adoptive TransferAdultCells, CulturedFemaleFusion Proteins, bcr-ablHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsT-Lymphocytes, CytotoxicFusion Proteins, bcr-ablProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06224049ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.